Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1499291 | 0.98 | GABRA1 (0.38) | GABRA1GABRG2GABRB3CCR2CALM1 | |
| SCHEMBL1499436 | 0.88 | GABRA1 (0.36) | GABRA1GABRG2GABRB3CCR2CYP19A1 | |
| SCHEMBL1499268 | 0.82 | HPGD (0.35) | GABRA1GABRG2GABRB3CCR2CYP19A1 | |
| SCHEMBL3395169 | 0.82 | ALOX5AP (0.36) | GABRA1GABRG2GABRB3CCR2NR3C1 | |
| SCHEMBL4530176 | 0.81 | ALOX5AP (0.35) | GABRA1GABRG2GABRB3CCR2NR3C1 | |
| SCHEMBL4538488 | 0.74 | USP2 (0.42) | NPSR1 | |
| SCHEMBL3395390 | 0.73 | USP2 (0.44) | NPSR1 | |
| SCHEMBL9804571 | 0.73 | L3MBTL1 (0.39) | GABRA1GABRG2GABRB3CYP19A1 | |
| SCHEMBL2960873 | 0.70 | CALM1 (0.58) | CALM1 | |
| SCHEMBL3428803 | 0.70 | NOS3 (0.31) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245123-B1 | METHODS FOR PRODUCING ALKYLATED 1,3 BENZENEDIAMINE COMPOUNDS | CHEMTURA CORP (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8563489-B2 | Alkylated 1,3-benzenediamine compounds and methods for producing same | CHEMTURA CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20090156449-A1 | ALKYLATED 1,3-BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME | LANXESS SOLUTIONS US INC. | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156449-A1 | ALKYLATED 1,3-BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME | BBOX1, ABHD5, BRD1 | GABRA1 2052/4885GABRG2 1864/4885GABRB3 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.